Clusterin在恶性肿瘤治疗中的研究进展  

Advances in research on the role of clusterin in treatment of human malignancies

作　　者：马晓[1] 李鹤成[1] 

机构地区：[1]复旦大学附属肿瘤医院胸外科,复旦大学上海医学院肿瘤学系,上海200032

出　　处：《肿瘤》2013年第4期368-371,共4页Tumor

基　　金：上海市青年科技启明星计划(跟踪)(编号:11QH1400600);国家自然科学基金资助项目(编号:81272608)

摘　　要：CLU(Clusterin)是一种广泛存在于人体组织和体液中的凋亡相关蛋白,在多种病理、生理过程(包括组织重构、再生、脂质转运、补体调节和细胞凋亡等)中发挥重要作用。研究发现,CLU在正常的成熟组织中低表达,而选择性地在某些恶性肿瘤中高表达。CLU有2种主要亚型:分泌型CLU和核型CLU,它们在人类恶性肿瘤中发挥不同的作用。在恶性肿瘤治疗中,以CLU为靶点的研究已逐步展开。CLU （Clusterin） is an apoptosis-related protein which widely exists in human tissues and body fluids. It plays an important role in various pathophysiological processes including tissue remodeling, reproduction, lipid transport, complement regulation, and apoptosis. It was reported that CLU exerts a low expression level in normal and mature tissues while a high expression level in certain malignant tumors. CLU appears to have two main isoforms including secreted form and nuclear form. These two isoforms of CLU play different roles in human malignancies. Currently, more studies focused on treatment targeting CLU are going on.

关 键 词：肿瘤 治疗 凋亡调节蛋白质类 CLUSTERIN 

分 类 号：R730.5[医药卫生—肿瘤]